📄 Weekly Report May 18, 2026 (PDF) — Download
🎙 Podcast May 18, 2026 (MP3) — Play & Download
iPS Cells & Regenerative Medicine Weekly Report May 18, 2026
- Lonza Reports Strong Q1 2026 Performance, Driven by Robust CDMO Growth and Strategic Transformation into Pure-Play Biopharma Partner
- Hydrogen Energy Weekly Report May 18, 2026
Author of this article
関連記事
-
iPS Cells & Regenerative Medicine Weekly Report May 24, 2026 -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
-
iPSC-Derived Retinal Sheet Transplantation for Retinitis Pigmentosa: Clinical Trial Validates Long-Term Safety and Engraftment
-
SelectBIO to Host Lipid Nanoparticles (LNPs) Asia/Pacific 2026: Driving mRNA Delivery Innovations
-
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
-
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
-
iRegene Therapeutics’ NouvNeu001 Secures Dual FDA Expedited Designations: A New Regulatory Milestone for iPSC Therapies
-
CRISPR Therapeutics Honored with 2026 Global Recognition Award for Pioneering Gene-Editing Advances
Comments